Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Safety personalisation of ART therapy: what treatments do patients receive with the knowledge of their HLA-B*5701 status? ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1, 12.2008
- Urheber
-
Rubio, R.
- Beteiligte Personen und Organisationen
-
Johnson, MA
Haas, BJ
Loeschel, EA
Granier, C.
Jackson, F.
Pearce, HC
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P83
- URN
-
urn:nbn:de:1111-2016052053686
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rubio, R.
- Johnson, MA
- Haas, BJ
- Loeschel, EA
- Granier, C.
- Jackson, F.
- Pearce, HC
- SpringerLink (Online service)
Ähnliche Objekte (12)
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701
Gebäudebeschreibungen Nr. 5701-5899
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701
Gebäudebeschreibungen Nr. 5701-5899
Peptide binding specificities of HLA-B*5701 and B*5801
5701
5701. - 5750.
57.01. Jahresrechnungen
NW 57/01 - 07 NO 57/01 - 07
HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
The molecular basis of differential immunological HLA-B*57:01-associated adverse drug reactions
Cost-effectiveness analysis of HLA-B*5701 screening in preventing abacavir hypersensitivity in Spain
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
HLA-B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity
381-390, 5535-5701